BUYINS.NET: LXRX, EXAS, SNTA, ASIA, SPPI, VTNC Expected To Be Down Before Next Earnings Releases
(M2 PressWIRE Via Acquire Media NewsEdge) BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. Lexicon Pharmaceuticals Inc (NASDAQ:LXRX), Exact Sciences Corp (NASDAQ:EXAS), Synta Pharmaceuticals Corp (NASDAQ:SNTA), Asiainfo Linkage Inc (NASDAQ:ASIA), Spectrum Pharmaceuticals Inc (NASDAQ:SPPI), VITRAN CORP INC (NASDAQ:VTNC) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
Symbol Company # of Reports Quarter Release Date
LXRX Lexicon Pharmaceuticals Inc 12 Quarter Q1 05/02/2013
EXAS Exact Sciences Corp 6 Quarter Q1 04/30/2013
SNTA Synta Pharmaceuticals Corp 12 Quarter Q1 04/30/2013
ASIA Asiainfo Linkage Inc 6 Quarter Q1 04/27/2013
SPPI Spectrum Pharmaceuticals Inc 6 Quarter Q1 04/25/2013
VTNC VITRAN CORP INC 6 Quarter Q1 04/25/2013
This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) - Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of drug programs in various stages of clinical development include LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2, which is in Phase IIb clinical trials for the treatment of type 2 diabetes; LX1032, an inhibitor of tryptophan hydroxylase, is preparing for Phase III registrational trials to reduce peripheral serotonin production without affecting brain serotonin levels in patients with carcinoid syndrome, as well as initiated a Phase II proof-of-concept trial for patients with ulcerative colitis; and LX1033, a serotonin synthesis inhibitor that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company also develops LX2931, an inhibitor of sphingosine-1-phosphate lyase, which completed a Phase IIa clinical trials and conducting a dose-ranging study to explore higher doses as a treatment for rheumatoid arthritis and other autoimmune diseases; and LX7101, an orally-delivered small molecule compound that initiated a Phase I-II proof-of-concept study in glaucoma patients. It also has advanced small molecule compounds from various additional drug programs into various stages of preclinical development and research. The company has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas..
Exact Sciences Corp (NASDAQ:EXAS) - Exact Sciences Corporation, a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect each of the four stages of colorectal cancer, as well as pre-cancerous lesions. Its test includes proprietary and patented methods, which isolate and analyze the trace amounts of human DNA that are shed into stool every day from the exfoliation of cells that line the colon. The company s Cologuard test is also used to detect blood in stool, utilizing an antibody-based fecal immunochemical test. It has a strategic alliance agreement with LabCorp under which it licenses its patents and patent applications relating to the stool-based colorectal cancer screening technology to LabCorp; a collaboration, license, and purchase agreement with Genzyme Corporation to deliver intellectual property improvements through licenses; and a license agreement with MAYO Foundation for medical education and research. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin..
Synta Pharmaceuticals Corp (NASDAQ:SNTA) - Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its oncology product portfolio includes Ganetespib, an Hsp90 inhibitor in phase 2b/3 clinical trial for various types of cancers, including non-small cell lung cancer, anaplastic lymphoma kinase, breast cancer, gastric cancer, prostate cancer, colon cancer, pancreatic cancer, multiple myeloma, acute myeloid leukemia, rectal cancer, ocular melanoma, melanoma, and hepatocellular cancer; Elesclomol, a mitochondria-targeting agent in phase 2 clinical trails for ovarian cancer and phase 1 clinical trial for acute myeloid leukemia; STA-9584, a vascular disrupting agent in preclinical development stage for prostate cancer; and various Hsp90 inhibitors in preclinical development stage for cancers. The company s inflammatory diseases product portfolio includes CRACM ion channel inhibitors in preclinical development stage for autoimmune diseases, respiratory conditions, and transplantation; and IL-12/23 inhibitors in lead optimization stage for autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts..
Asiainfo Linkage Inc (NASDAQ:ASIA) - AsiaInfo-Linkage, Inc. provides telecommunications software solutions and information technology (IT) products and services to telecommunications carriers and operators, and cable television operators in the People s Republic of China. The company offers business and operation support systems product suites, including OpenBilling, a convergent billing solution for telecommunications operators; OpenCRM, a CRM solution suite for telecommunications operators; OpenBOSS, a carrier-class business operation support system solution; OpenBI, a carrier-class operating analysis and decision support system platform; OpenPRM, a system that calculates, manages, and reconciles payment for intercarrier network access. It also provides network management solutions comprising NetXpert, a data and Internet protocol network management solution; and OpenXpert, an integrated telecommunications network management system. In addition, the company offers service applications products, such as Mail Center, an online messaging software; Spam Patrol software for real time anti-spam control; and Net Disk, a network hard disk product, which facilitates Internet-based file transfer, sharing, and management, as well as supports other functions, such as data processing of short message folders and synchronization of mobile devices. Its service applications products also include Internet Short Messaging Gateway, a business support platform for value-added short messaging services; and Device Management Platform that enables mobile operators to manage various mobile devices and perform remote mobile device management, such as remote diagnosis and parameter setup. In addition, it offers software enhancement and maintenance, system integration, and other value-added IT consulting and planning services. The company was formerly known as AsiaInfo Holdings, Inc. and changed its name to AsiaInfo-Linkage, Inc. in July 2010. AsiaInfo-Linkage, Inc. was founded in 1993 and is headquartered in Beijing, China..
Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) - Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. It offers ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody; and FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, as well as to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists. The company also develops apaziquone that is under Phase 3 clinical trials for non-muscle invasive bladder cancer; and belinostat, which is under Phase 2 registrational trial for relapsed or refractory peripheral T-cell lymphoma. In addition, it develops ozarelix that is under randomized phase 2 clinical trial in prostate cancer patients; ortataxel, which has completed Phase 2 studies in solid tumor patients; lucanthone an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase 1 study is a peptide agonist of endothelin B receptors; and RenaZorb, a lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; with TopoTarget A/S for the development and commercialization of belinostat; and a co-development and commercialization agreement with Hanmi Pharmaceutical Company for SPI-2012. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada..
VITRAN CORP INC (NASDAQ:VTNC) - Vitran Corporation Inc. provides freight surface transportation and related supply chain services in Canada and the United States. The company operates in two segments, Less-Than-Truckload (LTL) Services, and Supply Chain Operation (SCO) Services. The LTL Services segment transports shipments in less-than-full trailer load quantities through freight service center networks. It offers over-the-road services; and delivers its freight shipments within one or two days in the United States, and offers next-day services in Canada. This segment operates 114 terminals with a total of 3,743 loading doors in the United States and a total of 552 loading doors in Canada. The SCO Services segment provides supply chain solutions and freight brokerage services. This segment engages in the management and transportation of goods, as well as provides information on goods that pass through the supply chain from manufacturer to end user. It also offers a range of services, including cross-docks, inventory management, flow-through distribution facilities, and distribution facilities, as well as over-the-road or intermodal freight brokerage services. As of December 31, 2011, this segment had approximately 2.0 million square feet of warehouse and distribution space under management. It operates 16 facilities for retailers, including 6 in Canada and 10 in the United States. The company was founded in 1981 and is based in Toronto, Canada..
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Thomas Ronk, CEO
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to email@example.com)).
(c) 2013 M2 COMMUNICATIONS
[ Back To SIP Trunking Home's Homepage ]